3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) Flovent approved Q4 FY26; (2) Aumolertinib launches H2 FY27.
- Topline: 12–15% consolidated revenue growth (India 18–20%, EM 15–18%). RYALTRIS hits $200M by FY28.
- Bottomline: EBITDA margin expands to 25% (Flovent gross margin uplift, operating leverage). Net cash ~INR 800Cr.
- Margins: Gross margin recovers to 68–70% (respiratory mix shift).